Aa
Long term effect
Hi,
can someone pls tell me the lomg term effect of using nucleoside medication and alinia in treating hepb? Thanks
can someone pls tell me the lomg term effect of using nucleoside medication and alinia in treating hepb? Thanks
dont be too scared as said above few people experience sides but one thing is for sure long term use for decades is not healthy and only cirrhosis or severe damaged liver can justify such use so i'd definitely combo with other therapies so that nucs can be used short term
from latest easl conference we have now tests for sustained immune control of hbv
cccdna equal or less than 5 copies/cell
we now need an hbsag level equal to 5copies/cell, mybe hbsag 500iu/ml
tenofovir sides
http://www.drugs.com/mtm/tenofovir.html
just for comparison check also interferon sides, as i hve seen 2 family members on interferon i ve always been scared about it
http://www.drugs.com/mtm/peginterferon-alfa-2b.html
only few people experience sides, i am on etv almost 1year and a half, no sides but of course i make full blood tests every 3months, especially lactate at the begining
the only side effect i have to report is extreme irritability since the first week of use, no other sides
Immunologic
Immunologic side effects have included anaphylactoid reaction during postmarketing experience.
Psychiatric
Psychiatric side effects of moderate to severe intensity (Grade 2 to 4) have included insomnia (less than 1%).
Musculoskeletal
Musculoskeletal side effects have included arthralgia and myalgia.
entecavir
Dermatologic
Dermatologic side effects have included erythema. Rash and alopecia have been reported during postmarketing experience.
Hypersensitivity
Hypersensitivity side effects have included photosensitivity with lethargy in at least one patient, which resolved after stopping entecavir.
Entecavir Side Effects
Brand Names: Baraclude
Please note - some side effects for Entecavir may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Side Effects of Entecavir - for the Consumer
Entecavir
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Entecavir:
Diarrhea; dizziness; drowsiness; headache; indigestion; nausea; tiredness; trouble sleeping; vomiting.
Seek medical attention right away if any of these SEVERE side effects occur when using Entecavir:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); dark-colored urine; difficulty breathing; fast or irregular heartbeat; feeling cold, especially in the arms or legs; light-colored bowel movements; loss of appetite for several days; muscle pain; severe dizziness or lightheadedness; severe or prolonged nausea or vomiting; severe tiredness; stomach pain (with or without nausea or vomiting); weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Entecavir Solution
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Entecavir Solution:
Diarrhea; dizziness; drowsiness; headache; indigestion; nausea; tiredness; trouble sleeping; vomiting.
Seek medical attention right away if any of these SEVERE side effects occur when using Entecavir Solution:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); dark-colored urine; difficulty breathing; fast or irregular heartbeat; feeling cold, especially in the arms or legs; light-colored bowel movements; loss of appetite for several days; muscle pain; severe dizziness or lightheadedness; severe or prolonged nausea or vomiting; severe tiredness; stomach pain (with or without nausea or vomiting); weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Top
Side Effects by Body System - for Healthcare Professionals
General
The most common side effects reported in patients with chronic hepatitis B virus (HBV) infection and compensated liver disease during clinical trials have included headache, fatigue, dizziness, and nausea. One percent of patients discontinued treatment due to side effects or laboratory abnormalities (compared to 4% of lamivudine-treated patients).
The most common side effects reported in patients with chronic HBV infection and evidence of hepatic decompensation (n=102) through Week 48 of a study have included peripheral edema, ascites, pyrexia, hepatic encephalopathy, and upper respiratory infection. Eighteen percent of patients treated with entecavir died during the first 48 weeks of therapy (compared to 20% of adefovir-treated patients). The majority of deaths (11 of 18 entecavir-treated patients and 16 of 18 adefovir-treated patients) were due to liver-related causes such as hepatic failure, hepatic encephalopathy, hepatorenal syndrome, and upper gastrointestinal hemorrhage. Five percent of patients discontinued entecavir or adefovir due to a side effect through 48 weeks of therapy.
Hepatic
Hepatic side effects have included elevated ALT (greater than 10 times ULN and greater than 2 times baseline: 2%; greater than 5 times ULN: up to 12%) and total bilirubin (greater than 2.5 times ULN; up to 3%). Elevated AST and ALT flares have also been reported. Hepatic encephalopathy (10%) and deaths due to liver-related causes (such as hepatic failure, hepatic encephalopathy, and hepatorenal syndrome) have been reported in entecavir-treated patients with hepatic decompensation. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside/nucleotide analogs alone or in combination with other antiretroviral agents. Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of entecavir. Increased transaminases have been reported during postmarketing experience.
Posttreatment exacerbations of hepatitis or ALT flare, as defined by ALT greater than 10 times ULN and greater than 2 times baseline, have been reported in patients who discontinued treatment at or after 52 weeks after achieving a defined treatment response (nucleoside-naive HBeAg-positive, 2%; nucleoside-naive HBeAg-negative, 8%; lamivudine-refractory, 12%). The median time to exacerbation was 23 to 24 weeks. The rate may be higher in patients who discontinue entecavir without regard to treatment response.
Other
Other side effects of moderate to severe intensity (Grade 2 to 4) have included fatigue (up to 3%). Fever, accidental injury, influenza, and back pain have also been reported. Peripheral edema (16%), ascites (15%), and pyrexia (14%) have been reported in entecavir-treated patients with hepatic decompensation.
Metabolic
Metabolic side effects have included elevated lipase (greater than or equal to 2.1 times ULN; 7%), fasting hyperglycemia (greater than 250 mg/dL; up to 3%), elevated alkaline phosphatase, and elevated amylase. Decreased blood bicarbonate has been reported in 2% of entecavir-treated patients with hepatic decompensation. Lactic acidosis has been reported during postmarketing experience.
Genitourinary
Genitourinary side effects have included hematuria (Grade 3 to 4; 9%), glycosuria (Grade 3 to 4; 4%), and dysuria.
Renal
Renal side effects have included confirmed creatinine increases of 0.5 mg/dL or more (up to 2%). A confirmed increase in serum creatinine of 0.5 mg/dL (11%) and renal failure (less than 1%) have been reported in entecavir-treated patients with hepatic decompensation.
Respiratory
Respiratory side effects have included upper respiratory tract infection, cough, nasopharyngitis, and rhinitis. Upper respiratory infection has been reported in 10% of entecavir-treated patients with hepatic decompensation.
Gastrointestinal
Gastrointestinal side effects of moderate to severe intensity (Grade 2 to 4) have included diarrhea (up to 1%), dyspepsia (up to 1%), nausea (less than 1%), and vomiting (less than 1%). Abdominal pain (unspecified) and upper abdominal pain have also been reported. Deaths due to gastrointestinal hemorrhage were reported in entecavir-treated patients with hepatic decompensation.
Oncologic
Oncologic side effects have included malignant neoplasms occurring at a rate of 8.4 per 1000 patient-years. Hepatocellular carcinoma has been reported in 6% of entecavir-treated patients with hepatic decompensation.
Nervous system
Nervous system side effects of moderate to severe intensity (Grade 2 to 4) have included headache (up to 4%), dizziness (less than 1%), and somnolence (less than 1%).
Hematologic
Hematologic side effects have included decreased albumin (less than 2.5 g/dL) and platelets (less than 50,000/mm3) in less than 1% of patients.
Brand Names: Baraclude
Please note - some side effects for Entecavir may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).
Side Effects of Entecavir - for the Consumer
Entecavir
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Entecavir:
Diarrhea; dizziness; drowsiness; headache; indigestion; nausea; tiredness; trouble sleeping; vomiting.
Seek medical attention right away if any of these SEVERE side effects occur when using Entecavir:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); dark-colored urine; difficulty breathing; fast or irregular heartbeat; feeling cold, especially in the arms or legs; light-colored bowel movements; loss of appetite for several days; muscle pain; severe dizziness or lightheadedness; severe or prolonged nausea or vomiting; severe tiredness; stomach pain (with or without nausea or vomiting); weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Entecavir Solution
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Entecavir Solution:
Diarrhea; dizziness; drowsiness; headache; indigestion; nausea; tiredness; trouble sleeping; vomiting.
Seek medical attention right away if any of these SEVERE side effects occur when using Entecavir Solution:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); dark-colored urine; difficulty breathing; fast or irregular heartbeat; feeling cold, especially in the arms or legs; light-colored bowel movements; loss of appetite for several days; muscle pain; severe dizziness or lightheadedness; severe or prolonged nausea or vomiting; severe tiredness; stomach pain (with or without nausea or vomiting); weakness; yellowing of the skin or eyes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Top
Side Effects by Body System - for Healthcare Professionals
General
The most common side effects reported in patients with chronic hepatitis B virus (HBV) infection and compensated liver disease during clinical trials have included headache, fatigue, dizziness, and nausea. One percent of patients discontinued treatment due to side effects or laboratory abnormalities (compared to 4% of lamivudine-treated patients).
The most common side effects reported in patients with chronic HBV infection and evidence of hepatic decompensation (n=102) through Week 48 of a study have included peripheral edema, ascites, pyrexia, hepatic encephalopathy, and upper respiratory infection. Eighteen percent of patients treated with entecavir died during the first 48 weeks of therapy (compared to 20% of adefovir-treated patients). The majority of deaths (11 of 18 entecavir-treated patients and 16 of 18 adefovir-treated patients) were due to liver-related causes such as hepatic failure, hepatic encephalopathy, hepatorenal syndrome, and upper gastrointestinal hemorrhage. Five percent of patients discontinued entecavir or adefovir due to a side effect through 48 weeks of therapy.
Hepatic
Hepatic side effects have included elevated ALT (greater than 10 times ULN and greater than 2 times baseline: 2%; greater than 5 times ULN: up to 12%) and total bilirubin (greater than 2.5 times ULN; up to 3%). Elevated AST and ALT flares have also been reported. Hepatic encephalopathy (10%) and deaths due to liver-related causes (such as hepatic failure, hepatic encephalopathy, and hepatorenal syndrome) have been reported in entecavir-treated patients with hepatic decompensation. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside/nucleotide analogs alone or in combination with other antiretroviral agents. Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of entecavir. Increased transaminases have been reported during postmarketing experience.
Posttreatment exacerbations of hepatitis or ALT flare, as defined by ALT greater than 10 times ULN and greater than 2 times baseline, have been reported in patients who discontinued treatment at or after 52 weeks after achieving a defined treatment response (nucleoside-naive HBeAg-positive, 2%; nucleoside-naive HBeAg-negative, 8%; lamivudine-refractory, 12%). The median time to exacerbation was 23 to 24 weeks. The rate may be higher in patients who discontinue entecavir without regard to treatment response.
Other
Other side effects of moderate to severe intensity (Grade 2 to 4) have included fatigue (up to 3%). Fever, accidental injury, influenza, and back pain have also been reported. Peripheral edema (16%), ascites (15%), and pyrexia (14%) have been reported in entecavir-treated patients with hepatic decompensation.
Metabolic
Metabolic side effects have included elevated lipase (greater than or equal to 2.1 times ULN; 7%), fasting hyperglycemia (greater than 250 mg/dL; up to 3%), elevated alkaline phosphatase, and elevated amylase. Decreased blood bicarbonate has been reported in 2% of entecavir-treated patients with hepatic decompensation. Lactic acidosis has been reported during postmarketing experience.
Genitourinary
Genitourinary side effects have included hematuria (Grade 3 to 4; 9%), glycosuria (Grade 3 to 4; 4%), and dysuria.
Renal
Renal side effects have included confirmed creatinine increases of 0.5 mg/dL or more (up to 2%). A confirmed increase in serum creatinine of 0.5 mg/dL (11%) and renal failure (less than 1%) have been reported in entecavir-treated patients with hepatic decompensation.
Respiratory
Respiratory side effects have included upper respiratory tract infection, cough, nasopharyngitis, and rhinitis. Upper respiratory infection has been reported in 10% of entecavir-treated patients with hepatic decompensation.
Gastrointestinal
Gastrointestinal side effects of moderate to severe intensity (Grade 2 to 4) have included diarrhea (up to 1%), dyspepsia (up to 1%), nausea (less than 1%), and vomiting (less than 1%). Abdominal pain (unspecified) and upper abdominal pain have also been reported. Deaths due to gastrointestinal hemorrhage were reported in entecavir-treated patients with hepatic decompensation.
Oncologic
Oncologic side effects have included malignant neoplasms occurring at a rate of 8.4 per 1000 patient-years. Hepatocellular carcinoma has been reported in 6% of entecavir-treated patients with hepatic decompensation.
Nervous system
Nervous system side effects of moderate to severe intensity (Grade 2 to 4) have included headache (up to 4%), dizziness (less than 1%), and somnolence (less than 1%).
Hematologic
Hematologic side effects have included decreased albumin (less than 2.5 g/dL) and platelets (less than 50,000/mm3) in less than 1% of patients.
among the two i'd go for tenofovir because you can see if kidneys damage happens, while bone mineral density can be boosted by vitamin d and calcium
tenofovir is more potent than etv and has 0% resistance to date, in use since 2000
if you mean sides effect:
alinia, so mild that no need to menthion, allowed on 1 yo babies, in use since 2000 in south american countires first and US in 2004 i think bt not sure if earlier in US too
nucs:
endless possibilities but since there has been even deaths i would menthion the most serious, if you like we can talk about the less serious later
entecavir, in use since 2005, lumg cancers onmice labs so under strict control as regards
cancerogenity.i noticed 1mg versionhas a little high percentage of cancers even if not statistically significant
fatal cases of lactic acidosis, happened rarely and on severey damaged livers so lactate must be regularly checked during etv tx
fatty liver
tenofovir, kidneys damage, reduced bone mineral density
the other nucs are not on guidelines as first therapy due to resistance development
i am on etv+alinia but i'd like to stay on etv as little as possible obviously, no sides so far but nobody knows if 10-20 years of use can make cancer
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
